Core Viewpoint - Obesity is a significant global public health crisis linked to various chronic diseases, characterized by persistent low-grade inflammation that exacerbates disease progression [6][7]. Group 1: Research Findings - A study published in Science reveals that obesity reshapes macrophage nucleotide metabolism, leading to hyperactivation of the NLRP3 inflammasome and uncontrolled inflammation, accelerating disease progression [3][4]. - The study identifies SAMHD1 as an intrinsic inhibitor in macrophages that can suppress NLRP3 inflammasome activation across species from fish to humans [3]. Group 2: Mechanisms of Inflammation - The NLRP3 inflammasome acts as an "alarm" in the immune system, activated by tissue damage or stress, producing pro-inflammatory cytokines like IL-1β, which, in obesity, disrupt insulin signaling and accelerate metabolic diseases [9]. - Obese individuals exhibit an increased amount of oxidized mitochondrial DNA (ox-mtDNA) in their immune cells, which activates the NLRP3 inflammasome [11][12]. Group 3: Role of SAMHD1 - SAMHD1 is crucial for maintaining nucleotide balance in cells, and obesity leads to its phosphorylation and functional impairment, resulting in excessive NLRP3 inflammasome activation [14]. - The absence of functional SAMHD1 in animal models leads to NLRP3 hyperactivation, indicating its role as a regulatory mechanism against inflammation [14]. Group 4: Metabolic Reprogramming - Obesity alters the metabolic pathways in immune cells, allowing excess dNTPs to enter mitochondria via nucleotide transport proteins, bypassing normal synthesis pathways and leading to uncontrolled mtDNA synthesis [16]. - Blocking dNTP transport into mitochondria can reverse obesity-related inflammation, suggesting a potential therapeutic direction [16]. Group 5: Clinical Implications - Mice lacking SAMHD1 exhibit typical metabolic abnormalities after a high-fat diet, and blocking dNTP transport alleviates these symptoms [18]. - The study's findings indicate that targeting mitochondrial dNTP transport could lead to new therapies for chronic inflammation and metabolic diseases associated with obesity, offering a more precise approach than traditional immune response suppression methods [18].